A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis

Inclusion Criteria:

   - Diagnosis of myelofibrosis (primary, post-polycythemia vera, or post-essential
   thrombocythemia)

   - At least 18 years of age.

   - ECOG PS 0, 1, or 2.

Exclusion Criteria:

   - Any chemotherapy, immunomodulatory therapy, immunosuppressive therapy,
   corticosteroids, or growth factor treatment within 14 days prior to initiation of
   study drug.

   - Major surgery or radiation therapy within 28 days prior to initiation of study drug.